A matched cohort pharmacoepidemiological analysis of steroid free immunosuppression in renal transplantation

Transplantation

Volumn 87, Issue 5, 2009, Pages 672-680

  Barraclough, Katherine A ^a,b   Landsberg, David N ^a,b   Shapiro, R Jean ^a,b   Gill, John S ^a,b   Li, Guiyun ^a,b   Balshaw, Robert F ^a,b,c   Chailimpamontree, Worawon ^a,b   Keown, Paul A ^a,b,c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Complications; Corticosteroids; Graft rejection; Kidney transplantation

Indexed keywords

ANTIDIABETIC AGENT; BASILIXIMAB; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYMPHOBLAST ANTIBODY; METHYLPREDNISOLONE; OKT 3; PREDNISONE; TACROLIMUS; TRIACYLGLYCEROL; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT SURVIVAL; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIPOPROTEIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; CLASSIFICATION; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INCIDENCE; KIDNEY DISEASE; MIDDLE AGED; MORTALITY; SURVIVAL;

ADRENAL CORTEX HORMONES; ADULT; COHORT STUDIES; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 65649107275     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318195aa54     Document Type: Article

References (52)

1. Muller-Ruchholtz W. Glances at the history of transplantation immunology. Transplantation Proc 1999; 31: 1443.
2. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. Am J Med 1994; 96: 115.
3. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001; 72(12 suppl): S75.
4. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. Can Med Assoc J 1992; 147: 645.
5. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
6. Hricik DE, O'Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A metaanalysis. J Am Soc Nephrol 1993; 4: 1300.
7. Ponticelli C. Steroid-sparing strategies. Transplant Proc 2005; 37: 3597.
8. Keown PA. New immunosuppressive strategies. Curr Opin Nephrol Hypertens 1998; 7: 659.
9. Vincenti F. Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients. Transpl Int 2004; 17: 395.
10. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. transplantation 2000; 69: 2405.
11. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups [erratum in Transplantation 1997; 63: 618]. Transplantation 1997; 63: 39.
12. Kirk AD. Induction immunosuppression. Transplantation 2006; 82: 593.
13. Kaufman D, Shapiro R, Lucey M, et al. Immunosuppression: Practice and trends. Am J Transplant 2004; 4(suppl 9): 38.
14. Meier-Kriesche HU, Li S, Gruessner RWG, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6(5 pt 2): 1111.
15. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807.
16. Vítko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimenstacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: Results of the Atlas study. Transplantation 2005; 80: 1734.
17. Vincenti F, Schena F, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
18. Pascual J, Quereda C, Zamora J, et al, Spanish Group for Evidence-Based Medicine in Renal Transplantation. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: A meta-analysis of randomized, controlled trials. Transplantation 2004; 78: 1548.
19. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845.
20. Etminan M, Samii A. Pharmacoepidemiology I: A review of pharmaco-epidemiologic study designs. Pharmacotherapy 2004; 24: 964.
21. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Int Med 1999; 130: 461.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
23. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
24. Genuth S, Alberti KGMM, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus [see comment]. Diabetes Care 2003; 26: 3160.
25. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(suppl 1): S5.
26. * working group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
27. Borrows R, Chan K, Loucaidou M, et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. Transplantation 2006; 81: 125.
28. El-Faramawi M, Rohr N, Jespersen B. Steroid-free immunosuppression after renal transplantation-long-term experience from a single centre. Nephrol Dial Transplant 2006; 21: 1966.
29. Elster E, Leeser D, Morrissette C, et al. Obesity following kidney transplantation and steroid avoidance immunosuppression. Clin Transplant 2008; 22: 354.
30. Gallon L, Winoto J, Leventhal J, et al. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006; 1: 1029.
31. Heilman R, Reddy K, Mazur M, et al. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc 2006; 38: 1307.
32. Kato Y, Tojimbara T, Iwadoh K, et al. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Int Immunopharmacol 2006; 6:1984.
33. Khwaja K, Asolati M, Harmon J, et al. Outcome at 3 years with a prednisone-free maintenance regimen: A single-center experience with 349 kidney transplant recipients. Am J Transplant 2004; 4: 980.
34. Kandaswamy R, Melancon J, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients - An interim analysis. Am J Transplant 2005; 5: 1529.
35. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306.
36. Hennsessy S. Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 311.
37. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878.
38. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887.
39. MacDonald KM, Vancayzeele S, Deblander A, et al. Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: Application to mild and moderate dementia. Nurs Clin North Am 2006; 41: 105.
40. Boletis JN, Konstadinidou I, Chelioti H, et al. Successful withdrawal of steroid after renal transplantation. Transplant Proc 2001; 33:1231.
41. Kreis H, Cisterne J, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
42. Sola E, Alferez MJ, Cabello M, et al. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. Transplant Proc 2002; 34: 1689.
43. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365.
44. Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection [see comment]. Transplantation 2000; 70: 1352.
45. Gulanikar AC, Belitsky P, MacDonald AS, et al. Randomized controlled trial of steroids versus no steroids in stable cyclosporine-treated renal graft recipients. Transplant Proc 1991; 23(1 pt 2): 990.
46. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
47. Vanrenterghem Y, van Hooff JP, Squifflet J-P, et al. Minimization of immunosuppressive therapy after renal transplantation: Results of a randomized controlled trial. Am J Transplant 2005; 5: 87.
48. Opelz G, Dohler B, Laux G, Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005; 5(5 pt 1): 720.
49. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583.
50. Deinard AS, Page AR. A study of steroid-induced granulocytosis in a patient with chronic benign neutropenia of childhood. Br J Haematol 1974; 28: 333.
51. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060.
52. Naito T, Shinno K, Maeda T, et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull 2006; 29: 276.